Positron emission tomography (PET) studies using ^89Zr-labeled trastuzumab revealed that, even in HER2-overexpressing breast tumors, antibody distribution is markedly heterogeneous, with the formation of “pharmacological sanctuaries” nearly devoid of drug accumulation (206, 207). This evidence concerns the gene ERBB2 and breast neoplasm.